Grace Halsey

The 2 FDA-approved COVID-19 vaccines are similarly effective but also very different in a number of ways that will affect distribution.

An FDA panel voted to recommend the expanded use of sacubitril/valsartan for patients with heart failure with preserved ejection fraction.

Results of a new study suggest a simple clinical approach to assessing individuals at high risk of CHD who would benefit from targeted intervention.

A new Kaiser Family Foundation survey project found 85% of respondents trust their regular healthcare provider for information COVID-19 vaccination. PCPs, read more.

The rapid antigen test for the detection of active COVID-19 in those with and without symptoms produces results within 20 minutes and will retail for about $30.

Among patients with obesity who contracted COVID-19, those with a history of bariatric surgery had significantly decreased odds of hospitalization, a new study finds.

Vaccination against COVID-19 for US healthcare personnel began on December 14, 2020; the same day, CDC hosted a webinar on how to ensure HCP health and safety during this period.

Early COVID-19 vaccine demand will far exceed supply and so states have been refining distribution plans for months. Here is a topline review of what to expect.

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

A high-dose influenza vaccine was no more effective than the standard-dose vaccine at reducing the risk of severe outcomes among patients with heart disease, NIH study finds.

The CDC reduced the length of quarantine required for persons exposed to someone infected with SARS-CoV-2 from 14 days to 10 or to 7 with a negative test.

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.

DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.

The expanded indication for baloxavir marboxil is positive news as the surge in US COVID-19 cases converges with the arrival of flu season.

The AstraZeneca/Oxford vaccine candidate showed 90% efficacy in one dosing regimen; 62% in a second; and an average efficacy rate of 70%.

Once-weekly semaglutide 2.0 mg vs 1.0 mg led to statistically significant, superior reductions in A1c and weight in type 2 diabetes patients not at goal, study finds.

Increasing baseline FeNo levels were associated with reduced exacerbation and greater lung function improvement in dupilumab-vs-placebo-treated patients.

COVID-19 cases are surging across the country as the US heads into holiday season. Counsel patients on staying safe and keep these billing codes very close at hand.

Moderna announced safety and efficacy data from the phase 3 COVE trial that found mRNA-1273 94.5% effective in preventing infection with SARS-CoV-2.

AHA 2020: Daily supplementation with 2000 IU of vitamin D3/day and/or 840 mg omega-3 fatty acids/day did not reduce or increase risk of incident atrial fibrillation.

AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.

Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.

AHA 2020 Virtual Scientific Sessions: Nearly one-third of racial disparities in hypertension treatment may be linked to inequities in treatment intensification, study authors suggest.

AHA 2020 Virtual Scientific Sessions: Cumulative exposure, exposure intensity, and number of household smokers in childhood all impact adult heart function, study authors found.

AHA 2020 Virtual Scientific Sessions: Healthy lifestyle habits are inversely associated with-all cause mortality, study authors found.

The novel monoclonal antibody could bring relief to millions of persons with severe, uncontrolled asthma, including those with a low eosinophil phenotype.

Preview days 4 and 5 of the American Heart Association 2020 live late-breaking science sessions. Decide what you need to watch and when.

What to watch during the AHA 2020 late-breaking science sessions? We break down the first 3 days of clinical trial presentations for you, here.

Pfizer/BioNTech announced more than 90% efficacy for their vaccine against SARS-CoV-2 infection in the first interim analysis of phase 3 study.

FDA approval is based on results of the phase III THALES trial, in which DAPT with ticagrelor and aspirin for 30 days reduced the rate of stroke and death by 17% vs aspirin alone.